Claybrook Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
Claybrook Capital's PFE Position: Q3 2023 in Review
Claybrook Capital increased its Pfizer (PFE) stake by 2% in Q3 2023, buying an estimated $7.25K and bringing the position to 10,705 shares worth $355K. The position accounts for 0.2% of the portfolio, ranked #103.
Claybrook Capital first reported a position in PFE in Q4 2017 and has held it in 19 quarters since. The position peaked at $3.86M in Q2 2021. 2,926 funds tracked by Wall St. Rank hold PFE as of Q3 2023.
- Claybrook Capital held 10,705 shares of Pfizer worth $355K as of Q3 2023.
- Claybrook Capital bought 205 Pfizer shares in Q3 2023, an estimated $7.25K.
- Pfizer made up 0.2% of Claybrook Capital's portfolio in Q3 2023, its #103 holding.
- Claybrook Capital first reported a position in Pfizer in Q4 2017 and has held it in 19 quarters since.
- Claybrook Capital's Pfizer position peaked at $3.86M in Q2 2021.
- 2,926 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.
Based on Claybrook Capital's 13F filing for Q3 2023, filed 24 Oct 2023.